Gene Expression Profiling for Prognosis of a Non-Hodgkin Lymphoma
Description of Invention:
Diffuse large B cell lymphoma (DLBCL) is a quickly progressing cancer of the white blood cells, which is the most common type of non-Hodgkin lymphoma. Most commonly, DLBCL is treated aggressively with combination chemotherapy referred to as R-CHOP. Fortunately, with this treatment more than half of these patients can be cured or show remission. However, other patients do not respond to treatment and succumb to the disease. Therefore, it would be helpful to predict which patients are likely not to respond to R-CHOP and would benefit from alternate treatments.
This invention provides gene microarrays and method of use claims for a survival predictor calculated for DLBCL patients undergoing combination therapy. By measuring the gene expression of genes from cancer biopsies it is possible to identify patients that are unlikely to be cured by R-CHOP and could benefit from alternative treatments like anti-angiogenic drugs.
Applications:
Diagnostic test for managing treatment of DLBCL patients.
Design and analysis of clinical trials in DLBCL.
Market:
About 16,000 new cases per year of DLBCL in U.S.
Affects mostly the middle-aged but it can afflict children.
Patent Status:
DHHS Reference No. E-256-2008/0 --
U.S. Provisional Application No. 61/059,678 filed 06 Jun 2008
Relevant Publication: A Rosenwald et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jun 20;346(25):1937-1947. [PubMed abs]
Licensing Status: Available for exclusive or non-exclusive licensing.
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics
For Additional Information Please Contact: Sabarni K. Chatterjee Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-5587
Email: chatterjeesa@mail.nih.gov
Fax: 301/402-0220
